Guidelines for Authors

Manuscript will be carefully scrutinized for evidence of plagiarism, duplication and data manipulation; in particular, images will be carefully examined for any indication of intentional improper modification.

Any suspected misconduct ends up with a quick rejection and is then reported to the US Office of Research Integrity.

Ensure that your work is written in correct English before submission. Professional copyediting can help authors improve the presentation of their work and increase its chances of being taken on by a publisher. In case you feel that your manuscript would benefit from a professional a professional English language copyediting checking language grammar and style, you can find a reliable revision service at:

The Corresponding Author must submit the manuscript online-only through our Manuscript Submission System.

Authors are kindly invited to suggest potential reviewers (names, affilitations and email addresses) for their manuscript, if they wish.

Manuscript preparation

Manuscripts should be in either British or American English consistently throughout. Check for consistent spelling of names, terms, and abbreviations, including in tables and figure captions. Note that submitted manuscripts will not go through language-focused copyediting with the journal prior to or after acceptance; language-focused copyediting is the responsibility of the authors prior to submission.

Each manuscript has to be typewritten and double-spaced throughout;
pages should be in A4 format and numbered;
lines should be left numbered in continuum (10-digit numeric system).
The manuscript can be submitted either in Word or PDF format.


Declarations
All manuscripts must contain the following sections (compulsory):

  • Ethics approval
  • Availability of data and material
  • Competing interests
  • Funding
  • Authors' contributions
  • Acknowledgments

Please see below for details on the information to be included in these sections.

If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section. 

Ethics approval and consent to participate
Manuscripts reporting studies involving human participants, human data or human tissue must:
-include a statement on ethics approval and consent (even where the need for approval was waived)
-include the name of the Ethics Committee that approved the study and the committee’s protocol number.
Studies involving animals must include a statement on Ethics Approval and for experimental studies involving client-owned animals, authors must also include a statement on informed consent from the client or owner.
If your manuscript does not report on or involve the use of any animal or human data or tissue, please state “Not applicable” in this section.

Consent for publication
If your manuscript contains any individual person's data in any form (including any individual details, images, or videos), you must obtain permission to publish from that person, or, in the case of children, from their parent or legal guardian. All case report presentations must have permission to publish.
You should not submit the form to us immediately, but we may request a copy at any time (including after publication).
If your manuscript contains no data from any specific person, please indicate "Not applicable" in this section.

Availability of data and materials

All manuscripts must include a statement about the availability of data and materials. Data availability statements should include information on where to find data supporting the results reported in the article, such as hyperlinks to publicly archived datasets analyzed or generated during the study, if applicable. If your manuscript does not contain any data, please state 'Not applicable' in this section

Data availability statements can take one of the following forms (or a combination of several if multiple datasets are involved):

  • The datasets generated and/or analyzed during this study can be found in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS].
  • The datasets used and/or analyzed during the current study are available upon reasonable request from the corresponding author.
  • All data generated or analyzed during this study are included in this published article.
  • The datasets generated and/or analyzed during the current study are not publicly available due to [REASON WHY DATA ARE NOT PUBLIC], but are available upon reasonable request from the corresponding author.
  • The data that support the study's findings are available from [third party name], but there are restrictions on their availability because they were used under license for the current study and thus are not publicly available. However, the authors' data are available upon reasonable request and with the permission of [third party name].

Competing interest
This section requires the declaration of all competing financial and non-financial interests. Please contact the editorial office if you are unsure whether you or any of your co-authors have a competing interest. In this section, please use the authors' initials to refer to each author's competing interests.
If you have no competing interests, please state in this section "The authors declare that they have no competing interests".

Acknowledgements
Please acknowledge anyone who contributed to the article but does not meet the criteria for authorship, including anyone who provided professional writing services or materials. Authors should obtain permission to acknowledge all those mentioned in the Acknowledgements section.
If you do not have anyone to acknowledge, please write "Not applicable" in this section.

First and second pages

The first page must contain:

  1. title (lowercase), without acronyms;
  2. first name and family name of each author, separated by commas;
  3. affiliation(s) of each author (in English);
  4. acknowledgments;
  5. full name and full postal address of the corresponding author. Phone, fax number and e-mail address for the correspondence should also be included;
  6. three to five key words.

The second page should contain:

  1. authors' contributions, e.g., information about the contributions of each person named as having participated in the study (role of authors and contributors);
  2. all the above-detailed Declarations;
  3. further information (e.g., conference presentation).

Tables and Figures

If tables are used, they should be double-spaced on separate pages of the manuscript, not embedded throughout the text. They should be numbered and cited in the text. Tables should be provided as editable Word files, and authors should ensure that they are presented in a publication-ready format. Considering how a table fits on a page in a wordprocessing program can often provide insight into how it will appear on a journal page.

Larger or more complex tables will be made available online as supplementary material at the Editorial Office's sole discretion, including ensuring efficient readability of the paper publishing format.

If figures are used, they should be numbered and cited in the text and inserted at the end of the manuscript. Figures should be designed using a well-known software package. Please note that the Production Office will not redraw or re-letter any image.

A different caption for each figure must be provided at the end of the manuscript. Figures with different panels have to be grouped into a plate, and panels marked with letters.

In case of acceptance, authors are required to provide the figures as .tiff or .jpg files, with the following digital resolution:

  1. Color (saved as CMYK): 300 dpi - maximum width 17 cm - minimum width 8.5 cm
  2. Black and white/grays: 600 dpi - maximum width 17 cm - minimum width 8.5 cm

A different caption for each figure must be provided at the end of the manuscript, not included in the figure file.

Authors must obtain written permission for the reproduction and adaptation of material which has already been published. A copy of the written permission has to be provided before publication (otherwise the paper cannot be published) and appropriately cited in the figure caption. The procedure for requesting the permission is the responsibility of the Authors; PAGEPress will not refund any costs incurred in obtaining permission. Alternatively, it is advisable to use materials from other (free) sources.

Other

If abbreviations are used in the text, authors are required to write full name+abbreviation in brackets [e.g. Multiple Myeloma (MM)] the first time they are used, then only abbreviations can be written (apart from titles; in this case authors have to write always the full name).
If names of equipment or substances are mentioned in the text, brand, company names and locations (city and state) for equipment and substances should be included in parentheses within the text.

Journal Sections

  • Original Articles (3500 words max, abstract 180 words max, 40 references max, 3/5 tables and/or figures): In general, this kind of publication should be divided into an Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusions and References. A maximum of 10 authors is permitted and additional authors should be listed in an ad hoc Appendix.
  • Reviews (4000 words max, abstract 250 words max, minimum 40 references, 3/5 tables and/or figures): They should be introduced by a general summary of content in the form of an Abstract. Following a short introduction, putting the study into context and defining the aim, reviews will concentrate on the most recent developments in the field. A review should clearly describe the search strategy followed (key words, inclusion, exclusion criteria, search engines, ...). No particular format is required; headings should be used to designate the major divisions of the paper.
  • Brief Reports (about 2000 words, abstract 150 words max, 20 references max, 3 tables and/or figures): Short reports of results from original researches. They should be introduced by a general summary of content in the form of an Abstract. They must provide conclusive findings: preliminary observations or incomplete findings cannot be considered for publication.
  • Case Reports (about 2000 words, abstract 150 words max, 20 references max, 3 tables and/or figures): Reports describing observations on clinical cases that can be educational, including adverse effects of drugs or outcomes of a specific treatment. They should be divided into: Abstract, Introduction (optional), Case report(s), Discussion, Conclusions and References.
  • Letters to the Editor (800 words max): These are written on invitation, short essays that express the authors’ viewpoint, may respond to published manuscripts in our journals, or deliver information or news regarding an issue related to the Journal scope. If the letter relates to a published manuscript, the authors of the original manuscript will be given the opportunity to provide a respond. Authors of Letters to the Editor should provide a short title.
  • Book Reviews (no abstract, no references needed): They should be a short critical analysis and evaluation of the quality, meaning, and significance of a short book which addressed at least one of main topics of the Journal (the authors should contact the Editor-in-Chief of the journal for his/her approval before submitting a Book review).

For further details on the specific layout to follow for the different types of papers published by the Journal, please refer to the Section Policies.

References

References should be prepared strictly according to the Vancouver style. References must be numbered consecutively in the order in which they are first cited in the text (not alphabetical order), and they must be identified in the text by Arabic numerals in superscript. References in the main text must always be cited after dots and commas. References to personal communications and unpublished data should be incorporated in the text and not placed under the numbered references [Example: (Wright 2011, unpublished data) or (Wright 2011, personal communication)]. Where available, URLs for the references should be provided directly within the MS-Word document. References in the References section must be prepared as follows:

  1. more than three authors, cite 3 authors, et al. If the paper has only 4 authors, cite all authors;
  2. title style: sentence case; please use a capital letter only for the first word of the title;
  3. journal titles mentioned in the References list should be abbreviated according to the following websites:
    1. ISI Journal Abbreviations Index (http://library.caltech.edu/reference/abbreviations);
    2. Biological Journals and Abbreviations (http://home.ncifcrf.gov/research/bja);
    3. Medline List of Journal Titles (ftp://ftp.ncbi.nih.gov/pubmed/J_Medline.txt);
  4. put year after the journal name;
  5. never put month and day in the last part of the references;
  6. cite only the volume (not the issue in brackets);
  7. pages have to be abbreviated, e.g., 351-8.

To ensure the correct citation format, please check your references in the PubMed database (http://www.ncbi.nlm.nih.gov/pubmed).

Examples:

Standard journal article

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002;347:284-7.

Proceedings

Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, eds. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming, 2002 Apr 3-5, Kinsdale, Ireland. Berlin: Springer; 2002. pp 182-91.

Article with organization as author

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension 2002;40:679-86.

Books

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis, MO: Mosby; 2002.

Bjørn Lomborg, ed. RethinkHIV - Smarter ways to invest in ending HIV in Sub-Saharan Africa. Cambridge: Cambridge University Press; 2012.

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, eds. The genetic basis of human cancer. New York, NY: McGraw-Hill; 2002. pp 93-113.

Peer-review policy

All manuscripts submitted to our journal are critically assessed by external and/or in-house experts in accordance with the principles of peer review (http://www.icmje.org/#peer), which is fundamental to the scientific publication process and the dissemination of sound science. Each paper is first assigned by the Editors to an appropriate Associate Editor who has knowledge of the field discussed in the manuscript. The first step of manuscript selection takes place entirely in-house and has two major objectives: i) to establish the article appropriateness for our journals readership; ii) to define the manuscript priority ranking relative to other manuscripts under consideration, since the number of papers that the journal receives is much greater than it can publish. If a manuscript does not receive a sufficiently high priority score to warrant publication, the editors will proceed to a quick rejection. The remaining articles are reviewed by at least two different external referees (second step or classical peer review). Manuscripts should be prepared according to the Uniform Requirements established by the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/#prepare).

Authorship and Contributorship
All persons designated as authors should qualify for authorship according to the ICMJE criteria. Each author should have participated sufficiently in the work to take public responsibility for the content. Authorship credit should only be based on substantial contributions to: i) conception and design, or analysis and interpretation of data, and to ii) drafting the article or revising it critically for important intellectual content; and on iii) final approval of the version to be published; and iv) agreement to be accountable for all aspects of the work. Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is not sufficient for authorship. Authors should provide a brief description of their individual contributions. Those who do not meet all four criteria should not be listed as authors, but they should be acknowledged. Those whose contributions do not justify authorship may be acknowledged individually or together as a group under a single heading. Authors can find detailed information on the Publisher's web site.

Authors must disclose whether they used artificial intelligence (AI)-assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) in the creation of submitted work. Chatbots (such as ChatGPT) should not be listed as authors because they cannot be held accountable for the work's accuracy, integrity, and originality, all of which are required for authorship. Because AI can generate authoritative-sounding output that is incorrect, incomplete, or biased, authors should carefully review and edit the result. Authors should be able to assert that their paper contains no plagiarism, including text and images generated by AI.

Obligation to Register Clinical Trials 
The ICMJE believes that it is important to foster a comprehensive, publicly available database of clinical trials. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, etc. Our journals require, as a condition of consideration for publication, registration in a public trials registry. The journal considers a trial for publication only if it has been registered before the enrollment of the first patient. The journal does not advocate one particular registry, but requires authors to register their trial in a registry that meets several criteria. The registry must be accessible to the public at no charge. It must be open to all prospective registrants and managed by a non-profit organization. There must be a mechanism to ensure the validity of the registration data, and the registry should be electronically searchable. An acceptable registry must include a minimum of data elements (http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/). For example, ClinicalTrials.gov (http://www.clinicaltrials.gov), sponsored by the United States National Library of Medicine, meets these requirements.

Protection of Human Subjects and Animals in Research
When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. An Informed Consent statement is always required from patients involved in any experiments. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.  Further guidance on animal research ethics is available from the World Medical Association (2016 revision). When reporting experiments on ecosystems involving non-native species, Authors are bound to ensure compliance with the institutional and national guide for the preservation of native biodiversity.